Trials / Completed
CompletedNCT04269356
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants
Pharmacokinetics and Metabolism of a Single Dose of [14C] BMS-986256 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.
Detailed description
Recruitment temporarily on hold due to COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986256 | Specified dose on specified days |
| DRUG | Milk of magnesia | Specified dose on specified days |
Timeline
- Start date
- 2020-02-18
- Primary completion
- 2021-03-30
- Completion
- 2021-03-30
- First posted
- 2020-02-13
- Last updated
- 2022-01-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04269356. Inclusion in this directory is not an endorsement.